85 results about "Polymorphanisini" patented technology

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention provides a polymorphic form of a compound (Z)-3-{3-[3, 5-bis (trifluoromethyl) phenyl]-1H-1, 2, 4-triazole-1-yl}-N '-(pyrazine-2-yl) acryloyl hydrazide shown as a formula (I), and the polymorphic form provided by the invention has better chemical stability, physical stability and lower hygroscopicity, is less influenced by heat, humidity and illumination, and is convenient to store and prepare. The invention further provides a preparation method of the polymorphic form of the compound (Z)-3-{3-[3, 5-bis (trifluoromethyl) phenyl]-1H-1, 2, 4-triazole-1-yl}-N'-(pyrazine-2-yl) acryloyl hydrazide.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

The present invention provides a polymorph of a CDK9 inhibitor and a preparation method for the polymorph and use thereof. Specifically, disclosed are 4-(((4-(5-chloro-2-(((1R,4r)-4-(((R)-1-methoxypropyl-2-yl)amino)cyclohexyl)amino)pyridine-4-yl)thiazole-2-yl)amino)methyl)tetrahydro-2H-pyrano-4-methylnitrile maleate or fumarate or polymorphs thereof and applications thereof. In addition, also disclosed are a pharmaceutical composition containing the substance and an application of the pharmaceutical composition.

The present application relates to a kind of compound NMNH calcium salt, especially to a kind of reduced beta-nicotinamide mononucleotide calcium salt Polymorph and its preparation method, and they are used as pharmaceutical ingredients, health product ingredients, cosmetic ingredients or as food additive, and preparation containing these salts, belong to medicine, health product, cosmetic, food additive field.The specific, the present application describes NMNH calcium salt Polymorph, the crystal shows long-term sustained stability, significantly better than the stability of NMNH disodium salt, anti-hygroscopicity, more conducive to long-term storage, popularization and marketing.The NMNH calcium salt crystal preparation process is simple, easy to control, suitable for large-scale production.

Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and / or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and / or a psychiatric disorder in a subject.

Disclosed in the present invention are polymorphs of an IRAK-4 degrading agent. Specifically, the present invention provides a plurality of crystal forms of an IRAK-4 degrading agent represented by the following formula (I), salts thereof and crystal forms thereof, as well as a pharmaceutical composition thereof, the preparation therefor and the use thereof. The crystal forms provided by the present invention can be used for preparing drugs for treating and / or preventing IRAK4-mediated related diseases.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The present invention relates to novel polymorphic forms of Iptacopan hydrochloride and preparation thereof. The invention also relates to pharmaceutical composition comprising novel polymorphic forms of Iptacopan hydrochloride and their use in the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria.

The invention relates to a polymorphic form of hydrobromide or hydrochloride of 5-(6-(4-(cyclopropylmethyl) piperazine-1-yl)-2-methylpyridine-3-yl)-N-((4, 6-dimethyl-2-oxo-1, 2-dihydropyridine-3-yl) methyl)-3-(N-ethylcyclopropanecarboxamide)-2-methylbenzamide, a pharmaceutical composition of the polymorphic form and application of the polymorphic form and the pharmaceutical composition of the hydrobromide or hydrochloride of the 5-(6-(4-(cyclopropylmethyl) piperazine-1-yl)-2-methylpyridine-3-yl)-N-(4, 6-dimethyl-2-oxo-1, 2-dihydropyridine-3-yl)-3-(N-ethylcyclopropanecarboxamide.

Disclosed herein are novel polymorphs of Cabozantinib salts and to the process for preparation thereof.

The present invention relates to polymorphs of the hydrobromide salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazangrate), more specifically Form A, Form B, and Form C of the HBr salt of linaprazangrate. The present invention also relates to pharmaceutical compositions containing such polymorphs and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory or gastric acid-related diseases, particularly erosive gastroesophageal reflux disease (eGERD).

The present invention relates to a polymorph of the maleate salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazangrate), more particularly to linaprazangrate maleate Form 1. The present invention also relates to pharmaceutical compositions comprising such polymorph and to the use of this polymorph in the treatment or prevention of gastrointestinal inflammatory or gastric acid-related diseases, particularly erosive gastroesophageal reflux disease (eGERD).

The invention belongs to the technical field of pharmaceutical chemical crystallization, and particularly relates to tripterine, a crystal form of a solvate of the tripterine, a preparation method and application of the tripterine. The crystal form is a co-crystal of the tripterine and a solvent, and the ratio of the tripterine to the solvent is (45-200) mg: (1-30) mL. And the solvent is selected from C1-C4 alcohol solvents, C3-C5 ester solvents and non-polar solvents. 22 solvates and one novel polymorphic form are prepared by slurry conversion and solvent evaporation methods. The solvate is of a unique channel type structure, and solvent molecules are embedded into a three-dimensional framework constructed by a tripterine hydrogen bond network through hydrogen bonds and Van der Waals interaction. The stability of the crystal obtained by the polar solvent is obviously superior to that of the non-polar solvent, the structure-function relationship among the solvent polarity, the crystal structure and the thermal stability is clarified, and a theoretical basis and experimental guidance are provided for the preparation design of the tripterine medicine.

The application provides a polymorph of a compound of formula (A) (N-(1-((4-((3S,5S)-3,5-dimethylpiperazin-1-yl)phenyl)sulfonyl)piperidin-4-yl)-4-((S)-tetrahydrofuran-3-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-amine) and a polymorph of a phosphate salt of the compound of formula (A). The crystal form provided by the application has good chemical stability, physical stability and low hygroscopicity, is less affected by temperature, humidity and light, and is convenient to store and develop into a preparation.

The present invention relates to novel crystalline forms of butanedioic acid 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide of formula-la and process for preparation thereof.The present invention also relates to a process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide.Further, the present application also relates to acid addition salts of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide and process for the preparation thereof.

The application discloses a polymorph of a compound, a preparation method and application thereof. The crystal form III of compound A has characteristic peaks of X-ray powder diffraction expressed by 2θ angles at 12.15±0.20°, 15.98±0.20°, 16.62±0.20°, 17.14±0.20°, 24.32±0.20° and 26.08±0.20° using Cu-Kα radiation. The crystal form VII of compound A has characteristic peaks of X-ray powder diffraction expressed by 2θ angles at 12.94±0.20°, 14.41±0.20°, 15.64±0.20°, 17.25±0.20°, 21.75±0.20° and 24.23±0.20° using Cu-Kα radiation. The polymorph prepared by the application has good stability and can be stored stably under the condition of high temperature and low relative humidity.

The present application relates to a polymorphic form of a 2-(3-(3-amino-4-(7H-pyrrolo [2, 3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl) isonicotinoyl) piperidine-4-yl) azetidin-3-yl) acetonitrile compound of formula (I) and a pharmaceutical use thereof.

The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro- 1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.

The invention relates to a GPX4 protein inhibitor as well as a preparation method and application thereof. Specifically, the present invention relates to compounds of formula (I), pharmaceutically acceptable salts, N-oxides, hydrates, solvates, metabolites, polymorphs or prodrugs thereof, or tautomers, meso, racemes, enantiomers, diastereoisomers thereof, or mixtures thereof, the compound as shown in the formula (I) or the pharmaceutical composition thereof can selectively interfere with the activity of GPX4 so as to induce ferroptosis of tumor cells.

The present invention provides a crystalline form of (2R,3S)—N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinimide, represented by the structure of Compound (1), wherein the crystalline form comprises N-2 crystalline form, IPA2-1 crystalline form, M3-1 crystalline form, P4 crystalline form, P5 crystalline form, P6 crystalline form, or any combination thereof. The present invention also provides processes for the preparation of a the crystalline form, and pharmaceutical compositions comprising one or more of the crystalline forms.